Nifty
Sensex
:
:
9837.40
31524.68
-66.75 (-0.67%)
-270.78 (-0.85%)

Pharmaceuticals & Drugs

Rating :
24/99

BSE: 500660 | NSE: GLAXO

2395.80
3.25 (0.14%)
18-Aug-2017 | 3:57PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 2387.00
  • 2400.00
  • 2362.00
  • 2392.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 6629
  • 158.82
  • 3323.00
  • 2201.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,251.64
  • 69.61
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 19,320.50
  • 1.25%
  • 9.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75%
  • 0.5%
  • 11.8%
  • FII
  • DII
  • Others
  • 8.56%
  • 1.83%
  • 2.31%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Standalone Figures in Rs. Crores

Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Dec 07
Net Sales
2,999.99
2,837.91
3,362.91
2,607.70
2,692.06
2,455.38
2,151.06
1,907.77
1,693.41
1,608.21
Net Sales Growth
5.71%
-15.61%
28.96%
-3.13%
9.64%
14.15%
12.75%
12.66%
5.30%
 
Cost Of Goods Sold
1,489.27
1,324.90
1,327.66
1,171.68
1,100.57
923.50
785.73
700.01
650.18
642.66
Gross Profit
1,510.72
1,513.02
2,035.25
1,436.02
1,591.49
1,531.87
1,365.33
1,207.75
1,043.23
965.54
GP Margin
50.36%
53.31%
60.52%
55.07%
59.12%
62.39%
63.47%
63.31%
61.61%
60.04%
Total Expenditure
2,581.01
2,359.64
2,788.33
2,124.49
1,915.22
1,693.90
1,478.25
1,324.67
1,164.91
1,140.75
Power & Fuel Cost
27.82
25.97
31.17
23.85
22.50
26.70
26.75
24.66
24.75
20.54
% Of Sales
0.93%
0.92%
0.93%
0.91%
0.84%
1.09%
1.24%
1.29%
1.46%
1.28%
Employee Cost
483.01
443.37
493.02
362.05
295.52
278.36
234.53
203.97
168.36
151.67
% Of Sales
16.10%
15.62%
14.66%
13.88%
10.98%
11.34%
10.90%
10.69%
9.94%
9.43%
Manufacturing Exp.
108.26
118.09
367.24
127.78
113.62
111.44
67.51
60.08
52.65
51.38
% Of Sales
3.61%
4.16%
10.92%
4.90%
4.22%
4.54%
3.14%
3.15%
3.11%
3.19%
General & Admin Exp.
163.95
154.85
178.21
135.34
126.10
108.51
145.09
130.13
116.13
117.73
% Of Sales
5.47%
5.46%
5.30%
5.19%
4.68%
4.42%
6.75%
6.82%
6.86%
7.32%
Selling & Distn. Exp.
178.91
164.47
222.31
186.23
160.74
157.60
140.85
131.33
96.06
98.65
% Of Sales
5.96%
5.80%
6.61%
7.14%
5.97%
6.42%
6.55%
6.88%
5.67%
6.13%
Miscellaneous Exp.
129.80
127.99
168.72
117.55
96.17
87.78
72.33
73.30
60.61
98.65
% Of Sales
4.33%
4.51%
5.02%
4.51%
3.57%
3.58%
3.36%
3.84%
3.58%
3.78%
EBITDA
418.98
478.27
574.58
483.21
776.84
761.48
672.81
583.10
528.50
467.46
EBITDA Margin
13.97%
16.85%
17.09%
18.53%
28.86%
31.01%
31.28%
30.56%
31.21%
29.07%
Other Income
73.07
123.18
258.80
222.30
223.90
186.59
217.06
194.80
189.37
176.80
Interest
0.25
0.42
0.47
0.33
0.33
0.33
0.62
0.37
0.53
0.64
Depreciation
26.35
24.95
25.35
19.88
17.84
20.41
17.63
16.37
16.34
20.54
PBT
465.46
576.08
807.56
685.30
982.58
927.33
871.62
761.16
701.01
623.08
Tax
174.37
202.25
279.27
229.78
272.48
176.20
293.35
260.70
238.14
216.41
Tax Rate
34.11%
34.97%
36.96%
32.30%
32.66%
29.13%
33.66%
34.25%
33.97%
34.73%
PAT
336.81
376.14
476.41
481.67
561.88
428.59
578.27
500.46
462.87
406.67
PAT before Minority Interest
336.81
376.14
476.41
481.67
561.88
428.59
578.27
500.46
462.87
406.67
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
11.23%
13.25%
14.17%
18.47%
20.87%
17.46%
26.88%
26.23%
27.33%
25.29%
PAT Growth
-10.46%
-21.05%
-1.09%
-14.28%
31.10%
-25.88%
15.55%
8.12%
13.82%
 
Unadjusted EPS
39.76
44.41
56.24
56.87
66.34
50.60
66.18
59.96
69.78
64.64

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Dec 07
Shareholder's Funds
2,006.86
2,183.25
1,828.98
1,989.73
2,006.83
1,935.70
1,951.58
1,786.09
1,575.53
1,380.84
Share Capital
84.70
84.70
84.70
84.70
84.70
84.70
84.70
84.70
84.70
84.70
Total Reserves
1,922.15
2,098.55
1,744.28
1,905.03
1,922.13
1,851.00
1,866.88
1,701.39
1,490.83
1,296.14
Non-Current Liabilities
3,699.70
3,498.32
197.04
158.59
158.45
172.78
-51.43
-39.47
-24.13
-14.53
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.03
Unsecured Loans
0.99
1.60
2.63
3.61
4.14
4.59
5.16
5.42
5.65
5.77
Long Term Provisions
3,786.83
3,592.19
272.21
242.29
236.05
224.81
0.00
0.00
0.00
0.00
Current Liabilities
881.09
783.63
1,106.55
888.91
836.40
859.59
3,179.07
2,718.89
2,510.11
2,177.87
Trade Payables
278.93
327.74
308.04
285.63
237.37
200.58
334.36
294.42
255.08
228.33
Other Current Liabilities
390.47
202.82
130.09
84.13
86.82
67.25
12.60
22.78
20.65
18.77
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
211.69
253.08
668.42
519.15
512.21
591.77
2,832.12
2,401.69
2,234.38
1,930.77
Total Liabilities
6,587.65
6,465.20
3,132.57
3,037.23
3,001.68
2,968.07
5,079.22
4,465.51
4,061.51
3,544.18
Net Block
252.71
204.04
123.08
100.09
89.42
99.15
108.95
92.83
90.42
87.49
Gross Block
299.09
228.36
363.34
343.22
316.18
315.80
362.54
333.32
326.29
310.85
Accumulated Depreciation
46.38
24.32
240.26
243.13
226.76
216.65
253.59
240.49
235.87
223.36
Non Current Assets
4,752.54
4,087.05
545.58
413.30
355.01
363.01
235.57
262.64
751.21
766.86
Capital Work in Progress
605.46
267.67
115.22
61.86
43.79
16.19
8.72
21.36
9.95
5.43
Non Current Investment
5.40
6.04
0.06
0.06
10.06
54.98
117.90
148.46
650.84
673.94
Long Term Loans & Adv.
3,888.91
3,609.24
296.09
237.73
194.55
157.01
0.00
0.00
0.00
0.00
Other Non Current Assets
0.06
0.06
11.13
13.55
17.19
35.68
0.00
0.00
0.00
0.00
Current Assets
1,835.10
2,378.15
2,586.98
2,623.94
2,646.67
2,605.06
4,843.65
4,202.88
3,310.30
2,777.32
Current Investments
0.00
0.00
0.00
10.00
44.91
57.21
0.00
0.00
78.68
672.53
Inventories
425.80
525.87
375.58
346.97
285.15
333.44
285.55
257.30
232.98
211.21
Sundry Debtors
170.80
126.56
100.32
96.39
115.90
85.31
47.03
53.73
57.94
37.77
Cash & Bank
932.13
1,391.90
1,910.61
2,041.58
2,066.77
2,014.36
2,002.89
1,733.90
956.73
154.99
Other Current Assets
306.38
23.24
88.43
57.80
133.94
114.74
2,508.18
2,157.95
1,983.97
1,700.82
Short Term Loans & Adv.
286.63
310.58
112.04
71.19
58.18
50.12
2,454.34
2,127.55
1,938.04
1,671.82
Net Current Assets
954.01
1,594.52
1,480.43
1,735.03
1,810.27
1,745.46
1,664.58
1,483.98
800.18
599.45
Total Assets
6,587.64
6,465.20
3,132.56
3,037.24
3,001.68
2,968.07
5,079.22
4,465.52
4,061.51
3,544.18

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Dec 07
Cash From Operating Activity
236.00
138.90
337.64
281.31
313.59
335.37
479.36
511.51
330.03
318.83
PBT
465.46
576.08
807.56
685.30
982.58
927.33
871.62
761.16
701.01
623.08
Adjustment
-45.75
-96.01
-173.66
-156.37
-159.63
-139.38
-89.96
-69.78
-86.93
-55.78
Changes in Working Capital
-25.79
-124.41
-36.90
11.45
56.35
-73.09
12.66
20.47
-32.57
11.67
Cash after chg. in Working capital
393.91
355.67
597.00
540.37
879.30
714.86
794.32
711.85
581.51
578.98
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-160.59
-205.95
-252.43
-244.09
-318.38
-316.53
-313.89
-185.38
-246.43
-252.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
2.67
-10.82
-6.93
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
300.80
499.02
180.01
188.98
-109.65
358.03
86.76
660.78
826.92
98.86
Net Fixed Assets
-408.52
-61.62
-73.47
-45.11
-27.98
39.27
-16.58
-18.44
-19.96
-9.85
Net Investments
0.64
-5.96
10.00
44.92
57.21
0.55
30.56
560.97
581.44
-193.92
Others
708.68
566.60
243.48
189.17
-138.88
318.21
72.78
118.25
265.44
302.63
Cash from Financing Activity
-510.76
-638.33
-496.99
-494.14
-440.63
-394.81
-297.15
-394.84
-355.34
-298.49
Net Cash Inflow / Outflow
26.04
-0.42
20.66
-23.85
-236.69
298.59
268.97
777.45
801.61
119.20
Opening Cash & Equivalents
114.89
115.30
94.93
137.67
374.36
75.77
1,734.03
956.58
154.97
35.77
Closing Cash & Equivalent
140.92
114.89
115.59
113.82
137.67
374.36
2,003.01
1,734.03
956.58
154.97

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Dec 13
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Dec 07
Book Value (Rs.)
236.93
257.75
215.93
234.91
236.93
228.53
230.40
210.87
186.01
163.02
ROA
5.16%
7.84%
15.44%
15.95%
18.82%
10.65%
12.12%
11.74%
12.17%
12.35%
ROE
16.08%
18.75%
24.95%
24.10%
28.50%
22.05%
30.94%
29.77%
31.31%
31.46%
ROCE
24.40%
28.82%
39.53%
35.54%
42.24%
31.05%
46.54%
45.16%
47.28%
48.04%
Fixed Asset Turnover
11.38
9.59
9.82
8.13
8.74
7.40
6.31
5.91
5.61
5.74
Receivable days
18.09
14.59
10.35
14.45
13.29
9.62
8.38
10.45
9.77
10.25
Inventory Days
57.89
57.97
38.01
43.02
40.86
45.01
45.13
45.88
45.36
47.81
Payable days
51.56
53.81
43.72
49.18
47.40
62.14
88.58
85.41
86.80
86.34
Cash Conversion Cycle
24.42
18.75
4.64
8.28
6.75
-7.51
-35.07
-29.09
-31.66
-28.28
Total Debt/Equity
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest Cover
2045.74
1373.88
1612.26
2146.51
2497.59
1848.25
1403.44
2037.83
1334.73
978.85

News Update


  • Glaxosmithkline Pharma’s Q1 net dips 63% at Rs 26.42 crore
    26th Jul 2017, 12:10 PM

    Total income of the company decreased by 14.89% at Rs 620.75 crore for Q1FY18

    Read More
  • GlaxoSmithKline Pharma to invest Rs 1,000 crore in new unit in Karnataka
    10th Jul 2017, 11:46 AM

    The factory will commence production in 2018 and produce more than 8 billion tablets and 1 billion capsules a year

    Read More
  • Glaxosmithkline Phar - Quarterly Results
    19th May 2017, 12:00 AM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.